BPC-157 is angiogenic and nitric-oxide-pathway driven for systemic tissue repair (animal evidence only). GHK-Cu is a copper tripeptide with moderate human evidence for topical skin healing (Lorentic 2012, n=71 RCT; Draelos 2006) and no published human RCTs for the injectable use that gets marketed alongside it. BPC-157 is WADA S0 (athlete-prohibited at all times); topical GHK-Cu is not on the WADA list — the two peptides are not equivalent on regulation.
Both peptides address wound healing but live in different evidence worlds. BPC-157 has zero human RCTs for tendon / GI indications — the published evidence is animal-only and dominated by the Sikiric laboratory. GHK-Cu has moderate human evidence for the topical skin-healing endpoint (Lorentic 2012; Draelos 2006), and zero published human RCTs for the injectable use case that gets marketed alongside it. The popular framing of GHK-Cu as a "healing peptide" mostly maps to the topical Lorentic RCT — the injectable generalization is mechanism-only. This page synthesizes /bpc-157-research-summary and /ghk-cu-research-summary; it does not introduce new evidence.
Each row states a claim supported by a specific peer-reviewed citation. BPC-157 PMIDs link to PubMed records already cited in the BPC-157 deep-dive. GHK-Cu citations use author / journal / n where the underlying study is referenced that way in the existing deep-dives (no new PMIDs fabricated). Tier badges follow the four-tier evidence language used across all PeptideDecoded content (human RCT → human observational → animal / preclinical → mechanistic / anecdote).
| Claim | BPC-157 evidence | GHK-Cu evidence |
|---|---|---|
| Plausible mechanism | Strong preclinicalVEGF-driven angiogenesis, NO-pathway modulation, EGR-1 collagen signaling. PMID: 34139902 | Moderate (in vitro + topical human)Collagen I/III and elastin upregulation in fibroblasts; angiogenic and anti-inflammatory cytokine modulation. Mechanism first described by Pickart (1973) and replicated across in vitro / topical studies catalogued in the GHK-Cu research summary. |
| Tendon / ligament repair | Supportive (animal)Sikiric lab Achilles tendon and MCL repair models in rodents. PMID: 32628526 · PMID: 31800443 | None for tendon / ligament indicationGHK-Cu mechanism is fibroblast / collagen-dermis, not tendon or ligament. No animal or human tendon-specific data. |
| Wound healing (general) | Supportive (animal)Dermal wound models in rodents and pigs; Sikiric-lab VEGFR2 upregulation data. PMID: 31800443 · PMID: 34139902 | Moderate (topical)Lorentic et al. 2012 (n=71, double-blind RCT, Archives of Dermatological Research) supports topical GHK-Cu for skin elasticity / collagen density. Topical serum only. |
| GI mucosal healing | Strong (animal)Sikiric lab NSAID- and ethanol-induced gastric damage models — the original BPC-157 indication. PMID: 32628526 | NoneGHK-Cu's mechanism is fibroblast / dermal collagen, not GI mucosa. No animal or human GI data for GHK-Cu. |
| Skin / collagen outcome (topical) | NoneMechanism operates through VEGF / NO systemic pathways, not topical fibroblast signaling. No skin cosmetic RCT. | Moderate (topical)Lorentic 2012 RCT (n=71) supports improved skin elasticity, firmness, and collagen density vs vitamin C and tripeptide controls. Draelos 2006 (J Cosmet Dermatol) supports eye-cream outcomes vs placebo. |
| Scar / wound cosmetic outcome (topical) | Limited animalSikiric lab dermal wound models close faster but not framed as cosmetic endpoints. Animal-to-cosmesis translation not assumed. | Moderate (topical)Lorentic 2012 measured ultrasound-confirmed collagen density improvements in photoaged skin. Cosmetic-significant outcomes, but in a controlled RCT design. |
| Injectable wound healing (systemic) | Mechanism only (animal)Animal-only evidence; no completed human RCT. The injectable generalization is mechanism-driven, anchored to the Sikiric lab rodent data. PMID: 34139902 | NoneNo published human RCT for injectable GHK-Cu for any wound-healing indication. Popular injectable use sits outside any approved regulatory pathway and is mechanism-only. |
| Anti-aging / longevity (systemic) | NoneNo preclinical or clinical anti-aging outcomes for BPC-157. Wound-healing mechanism does not generalize to systemic longevity. | Topical only; injectable noneLorentic 2012 supports topical skin-aging outcomes. "Anti-aging" in the injectable sense has zero published human RCT. |
| Human randomized controlled trial (any indication) | NoneZero published human RCTs as of August 2026. | Topical RCTs exist; injectable noneTopical RCTs: Lorentic 2012 (n=71), Draelos 2006 (n=71). Injectable GHK-Cu: no published human RCT. |
| WADA status | Prohibited (S0 — at all times, no TUE pathway) | Topical not listed. Injectable unestablished for doping purposes. |
| FDA status | Not approved. Excluded from 503A compounding under FDA Category 2 bulk substance. | Cosmetic / GRAS topical. No injectable approval; injectable use sits outside any approved regulatory pathway. |
PMIDs (34139902, 32628526, 31800443) reused from the BPC-157 research summary and the BPC-157 deep-dive reference list — no new BPC-157 PMIDs introduced. GHK-Cu citations (Lorentic et al. 2012, Archives of Dermatological Research, n=71 RCT; Draelos et al. 2006, Journal of Cosmetic Dermatology) reused from the GHK-Cu research summary.
Three side-by-side cards. The "Route / dosing" rows reflect community-reported ranges from peptide forums and compounding pharmacies — they are not clinically validated dosing protocols, and no human RCT supports them for the popular endpoints.
Three honest verdicts. Each mirrors the same evidence-gap framing used in the underlying deep-dives — choosing one peptide over another does not establish human efficacy for either, it only frames where the animal / topical evidence is strongest.
BPC-157 is the more evidence-supported option when the use case targets a specific local tissue through vascular / NO / EGR-1 pathways. The Sikiric lab's tendon and GI data is the most extensive of any peptide commonly discussed in recovery communities (PMID: 32628526; PMID: 31800443). The mechanistic story is biologically plausible and consistent across multiple animal models. Caveats: zero human RCTs as of 2026, the evidence base is dominated by a single research group at the University of Zagreb with disclosed patent interests, BPC-157 is WADA S0 prohibited at all times, and it is excluded from 503A compounding under FDA Category 2.
The strongest human evidence for GHK-Cu is topical and cosmetic: the Lorentic 2012 RCT (n=71, Archives of Dermatological Research) and the Draelos 2006 study (J Cosmet Dermatol) both test a topical serum. These are legitimate, replicated outcomes — visible, measurable skin elasticity and collagen density improvements. Topical GHK-Cu is not WADA-listed and is cosmetic / GRAS. Caveats: "GHK-Cu injectable" is a separate question with no published human RCT. The online claim that topical efficacy implies injectable efficacy is mechanism-only and unsupported.
BPC-157 and topical GHK-Cu act on genuinely different biological targets: local VEGF / NO vascular perfusion (BPC-157) versus topical fibroblast / collagen I & III signaling (GHK-Cu). They hit different steps in different tissues. The stack is conceptually distinct from BPC-157 + TB-500, which share nearby mechanisms. Caveats: zero published human safety or efficacy data on the pair; athletes using BPC-157 face WADA S0 exposure regardless of the topical GHK-Cu component; BPC-157 is excluded from 503A compounding and GHK-Cu injectable sits outside any approved pathway; the combined risk profile is unknown.
"Evidence tier" and "delivery method" are the two fields most often conflated in this comparison. Four specific confusions to watch for:
For deeper context on how to evaluate any peptide claim — peer review, COI checks, red flags, and a 5-question pre-purchase checklist — see How to Verify Peptide Claims and the Editorial Standards page.
This comparison is the synthesis. The full evidence reviews are the underlying references — open either one if you want to evaluate a specific claim, verify a citation, or read the COI disclosure in detail.
Competitive athletes (asymmetric WADA exposure): BPC-157 is WADA S0 prohibited at all times — a positive test results in a full anti-doping rule violation with no Therapeutic Use Exemption pathway. Topical GHK-Cu, in contrast, is not on the WADA prohibited list; an athlete using only topical cosmetics does not face doping exposure. Injectable GHK-Cu's doping status is unestablished. The two peptides are not WADA-equivalent.
Anyone seeking an FDA-approved therapy: neither is approved for any indication. BPC-157 is excluded from 503A compounding under FDA Category 2. GHK-Cu is cosmetic / GRAS topical only; injectable GHK-Cu sits outside any approved regulatory pathway. Stacking amplifies regulatory exposure without adding evidence.
Anyone needing proven human efficacy: zero published human RCTs for BPC-157 at all (as of August 2026); zero published human RCTs for injectable GHK-Cu (only Lorentic 2012 / Draelos 2006 support topical skin outcomes). Community-reported outcomes are not clinical evidence. If you need a therapy with validated human efficacy for systemic wound healing or anti-aging, neither peptide is the right starting point — much less the combination.
This comparison page is a research summary, not medical advice. PeptideDecoded does not sell peptides, recommend vendors, provide dosing protocols, or make claims about safety or efficacy for any specific individual.
Work with a qualified physician who can evaluate your full medical history, current medications, and individual risk factors before making any decision about peptides — whether FDA-approved, compounded, or sold as research chemicals.